Most strikingly, treatment data on cell line, xenograft tumor, and autochthonous lung cancer in transgenic mouse models showed that combinational inhibition of TAK1 and MEK1/2 effectively shrank lung cancer concurrently positive for KRAS mutation and CLU deficiency. This evidence concerns the gene MAP2K1 and lung carcinoma.